RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

12 Oct 2016

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

Although Alnylam Pharmaceuticals Inc.'s recent safety crisis with Phase III candidate revusiran suggests that RNA interference therapies remain a long way from the market, RXi Pharmaceuticals Corp. thinks it has a unique approach with a shorter, self-delivering form of RNAi therapeutic that can solve the delivery issue safely and get ideal penetration into targeted areas in dermatology and ophthalmology.

In an interview with Scrip, RXi's CEO Geert Cauwenbergh, formerly CEO of New Jersey dermatology specialty firm Barrier Therapeutics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

10 Jul 2025

• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.